Jean-Claude Chomel

8PUBLICATIONS
22CO-AUTHORS
Cellular immunologyHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Medical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 28, 2023
Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with BCR::ABL1 from Chronic Myeloid Leukemia (CML) in Blast Crisis.

Lara Boucher, Nathalie Sorel, Christophe Desterke

|May 15, 2023
Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.

Thomas Systchenko, Jean-Claude Chomel, Pilar Gallego-Hernanz

|Oct 10, 2022
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).

Lydia Roy, Jean-Claude Chomel, Joëlle Guilhot

|Jan 23, 2021
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.

Francois Guilhot, Françoise Rigal-Huguet, Joëlle Guilhot

|May 28, 2020
Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.

Emilie Cayssials, Jose Torregrosa-Diaz, Pilar Gallego-Hernanz

|Mar 09, 2019
Long-term molecular remission in a patient with acute myeloid leukemia harboring a new NUP98-LEDGF rearrangement.

Maria Pilar Gallego Hernanz, José Miguel Torregrosa Diaz, Nathalie Sorel

Pageof 2

Frequent Collaborators

4 joint publications

Emilie Cayssials E

2 joint publications

Anna Raimbault

1 joint publications

Antoine Machet

1 joint publications

Francois Guilhot